Congenital fibrosarcoma. Preoperative chemotherapy and conservative surgery

Ninane, J.; Gosseye, Serge; Panteón, E; Claus, D.; Rombouts, Jean‐Jacques; Cornu, Guy

doi:10.1002/1097-0142(19861001)58:7<1400::aid-cncr2820580703>3.0.co;2-q

Cited by 71 publications

(36 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ninane et al9 reported the successful use of preoperative chemotherapy enabling limb sparing procedures for complete resection. Grier et al 6 reported (in 1984) on 2 patients treated for unresectable retroperitoneal fibrosarcoma with doxorubicin, vincristine, and cyclophosphamide, who were disease free at 4 years.…”

mentioning

confidence: 99%

Infantile Fibrosarcoma Successfully Treated With Chemotherapy, With Occurrence of Calcifying Aponeurotic Fibroma and Pleomorphic/Spindled Celled Lipoma at the Site 12 Years Later

Decomas

Heinrich²,

Craver

2009

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

The treatment of infantile fibrosarcoma has traditionally been wide resection. Chemotherapy has been investigated as an adjuvant and primary treatment in cases in which surgery would cause unacceptable morbidity. Recurrences normally occur within a year of completion of the chemotherapy and display the same histology. We present a child with an infantile fibrosarcoma of the elbow, successfully treated with chemotherapy alone, who developed a calcifying aponeurotic fibroma and a spindle cell/pleomorphic lipoma at the tumor site 12 years later.

show abstract

mentioning

confidence: 99%

Infantile Fibrosarcoma Successfully Treated With Chemotherapy, With Occurrence of Calcifying Aponeurotic Fibroma and Pleomorphic/Spindled Celled Lipoma at the Site 12 Years Later

Decomas

Heinrich²,

Craver

2009

Journal of Pediatric Hematology/Oncology

View full text Add to dashboard Cite

show abstract

“…Results of preoperative and/or postoperative CT in congenital ® brosarcoma were reported in several series [13,14] and proved to be an ef® cient treatment. The aim is to shrink the tumor and avoid a mutilating procedure or to treat minimal residual disease after conservative surgery, as we reported [15].…”

Section: Discussionmentioning

confidence: 97%

THE ROLE OF CHEMOTHERAPY IN CHILDHOOD SOFT TISSUE SARCOMAS OTHER THAN RHABDOMYOSARCOMAS: Experience of the Northern Israel Oncology Center

Weyl

Arush

Nahum

et al. 1999

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

Forty-three children with nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) were treated at the Northern Israel Oncology Center in Haifa, Israel, from 1971 to 1996. The male:female ratio was 1.5:1 and the median age of patient was 10 years (range, 3 months-18 years). The most common histopathologic diagnoses were fibrosarcoma (32.5%) and synovial sarcoma (16%). The sites of primary tumor were lower limb (35%), trunk (18%), upper limb (16%), head and neck (16%), and retroperitoneum (11%). By Intergroup Rhabdomyosarcoma Study classifications, 13 patients presented as group I, 15 patients as group II, 10 patients as group III, and 5 patients as group IV. Median follow-up time was 63 months (range, 6 months-18 years). The estimated survival after a 5-year period is 72% (SE +/- 17) for patients in group I, 75 +/- 15% in group II, 90 +/- 9% for patients in group III, and 40 +/- 21% for patients in group IV. Eleven patients relapsed; 4/6 who developed local relapse were cured and are alive with disease, while 4/5 who developed distant metastases are dead. For the 28 patients who underwent complete resection at diagnosis, the estimated survival after a 5-year period is 87 +/- 5% vs. 60 +/- 17% for the 15 patients who underwent partial excision or biopsy. Local radiotherapy was delivered after surgery to group III patients. Preoperative and postoperative chemotherapy was delivered to the patients of groups III and IV, and postoperative chemotherapy only to group II patients. Chemotherapy produced demonstrable gain in survival for group II and III patients but not for patients with metastases. The authors conclude that an aggressive surgical approach is needed in patients with NRSTS. Chemotherapy may help as a preoperative treatment in bulky disease or as a postoperative treatment for microscopic residual disease.

show abstract

“…This tumour should be initially treated by surgery alone with local excision of the lesion without impairing functionality. Occasionally adjuvant chemotherapy is advisable [9,11]. The risk of recurrence in further pregnancies is unknown.…”

Section: Discussionmentioning

confidence: 99%

Hydrops fetalis and fibrosarcoma: case report of an uncommon association

Navajas¹,

Astigarraga²,

Fdez-Teijeiro³

et al. 1996

Eur J Pediatr

View full text Add to dashboard Cite

show abstract

Congenital fibrosarcoma. Preoperative chemotherapy and conservative surgery

Abstract: Three cases of congenital fibrosarcoma are reported. The use of preoperative chemotherapy, a VAC regimen, allowed conservative surgery in two of them. The three children are well, with no evidence of disease and without sequelae after completion of postoperative chemotherapy.

Cited by 71 publications

References 15 publications

Infantile Fibrosarcoma Successfully Treated With Chemotherapy, With Occurrence of Calcifying Aponeurotic Fibroma and Pleomorphic/Spindled Celled Lipoma at the Site 12 Years Later

Infantile Fibrosarcoma Successfully Treated With Chemotherapy, With Occurrence of Calcifying Aponeurotic Fibroma and Pleomorphic/Spindled Celled Lipoma at the Site 12 Years Later

THE ROLE OF CHEMOTHERAPY IN CHILDHOOD SOFT TISSUE SARCOMAS OTHER THAN RHABDOMYOSARCOMAS: Experience of the Northern Israel Oncology Center

Hydrops fetalis and fibrosarcoma: case report of an uncommon association

Contact Info

Product

Resources

About